论文部分内容阅读
应用多聚酶链反应技术体外扩增２０例初治或复发的急性淋巴细胞白血病（ＡＬＬ）Ｔ细胞抗原受体，（ＴＣＲγ）基因重排，结果显示：１５例病人出现约４００ｂｐ的扩增产物，阳性检出率为７５％（１５／２０），产物电泳带位置略有差异提示其重排亚型的多样性。标准人急性Ｔ淋巴细胞白血病细胞株ＣＣＲＦ－ＣＥＭ细胞携带ＴＣＲγ基因重排，为阳性对照；而正常骨用及Ｒａｊｉ细胞检测阴性，为阴性对照。用系列稀释法证明本实验敏感性在１０－５水平以上。我们还探讨了该法在急性淋巴细胞白血病基因诊断、微量残留白血病细胞的监测及自体骨髓移植物体外净化效果的评价上的应用价值。该法不需寡核苷酸探针杂交、无需对扩增产物进行测序、且费时短、检出率高，提示有重要的临床意义。
In 20 cases of newly diagnosed or recurrent acute lymphoblastic leukemia (ALL) T cell antigen receptor (TCRγ) gene rearrangement by polymerase chain reaction amplification in vitro, the results showed that: 15 cases of patients with about 400bp amplification products, positive The detection rate was 75% (15/20), and there was a slight difference in the location of the product electrophoresis band, suggesting the diversity of rearranged subtypes. The standard human TCR cell line CCRF-CEM carries the TCRγ gene rearrangement as a positive control, whereas the normal bone marrow cells and Raji cells are negative for negative control. Serial dilution method to prove the sensitivity of the experiment in the 10-5 level above. We also discussed the value of this method in the gene diagnosis of acute lymphoblastic leukemia, the monitoring of trace residual leukemia cells and the in vitro purification of autologous bone marrow transplantation. This method does not require oligonucleotide probe hybridization, without the need for sequencing of amplification products, and time-consuming, high detection rate, suggesting an important clinical significance.